Phospholipase C Isozymes Are Deregulated in Colorectal Cancer – Insights Gained from Gene Set Enrichment Analysis of the Transcriptome by Danielsen, Stine A. et al.
Phospholipase C Isozymes Are Deregulated in Colorectal
Cancer – Insights Gained from Gene Set Enrichment
Analysis of the Transcriptome
Stine A. Danielsen
1,2, Lina Cekaite
1,2, Trude H. A ˚gesen
1,2, Anita Sveen
1,2, Arild Nesbakken
2,3, Espen
Thiis-Evensen
4", Rolf I. Skotheim
1,2, Guro E. Lind
1,2, Ragnhild A. Lothe
1,2*
1Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, 2Centre for Cancer Biomedicine, Faculty of Medicine, University
of Oslo, Oslo, Norway, 3Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway, 4Department of Organ Transplantation, Gastroenterology, and
Nephrology, Oslo University Hospital, Oslo, Norway
Abstract
Colorectal cancer (CRC) is one of the most common cancer types in developed countries. To identify molecular networks
and biological processes that are deregulated in CRC compared to normal colonic mucosa, we applied Gene Set Enrichment
Analysis to two independent transcriptome datasets, including a total of 137 CRC and ten normal colonic mucosa samples.
Eighty-two gene sets as described by the Kyoto Encyclopedia of Genes and Genomes database had significantly altered
gene expression in both datasets. These included networks associated with cell division, DNA maintenance, and
metabolism. Among signaling pathways with known changes in key genes, the ‘‘Phosphatidylinositol signaling network’’,
comprising part of the PI3K pathway, was found deregulated. The downregulated genes in this pathway included several
members of the Phospholipase C protein family, and the reduced expression of two of these, PLCD1 and PLCE1, were
successfully validated in CRC biopsies (n=70) and cell lines (n=19) by quantitative analyses. The repression of both genes
was found associated with KRAS mutations (P=0.005 and 0.006, respectively), and we observed that microsatellite stable
carcinomas with reduced PLCD1 expression more frequently had TP53 mutations (P=0.002). Promoter methylation analyses
of PLCD1 and PLCE1 performed in cell lines and tumor biopsies revealed that methylation of PLCD1 can contribute to
reduced expression in 40% of the microsatellite instable carcinomas. In conclusion, we have identified significantly
deregulated pathways in CRC, and validated repression of PLCD1 and PLCE1 expression. This illustrates that the GSEA
approach may guide discovery of novel biomarkers in cancer.
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Introduction
Colorectal cancer (CRC; MIM#114500) ranks third in cancer
incidence world-wide with an estimated 1.2 million new cases per
year [1]. According to the American Joint Committee on Cancer
(AJCC) the 5-year survival rates for patients diagnosed with stage I
and stage IV CRC, are 93% and 8% respectively, thus patient
prognosis is highly dependent on the tumor stage at diagnosis [2].
CRC develops through distinct histopathological stages from benign
precursor lesions to malignant tumors, known as the adenoma-
carcinoma sequence. The development is driven by progressive
accumulation of genetic and epigenetic alterations of specific genes,
and conserved signaling networks that exert pleiotropic effects on the
cancer cells are often targeted. Typically, malignant tumors are
characterized by the molecular phenotypes microsatellite instability
(MSI),chromosomal instability (CIN),and theCpG island methylator
phenotype (CIMP) [3]. The most commonly altered genes during
CRC development make up the basis for these phenotypes and
involve several signaling pathways and networks (Figure 1A).
Messenger RNA (mRNA) expression profiling studies have
provided improved understanding of the roles of several genes
important in initiation and progression of cancer, including CRC
[4]. Despite increasing knowledge of expression patterns of
individual genes, as well as promising gene signatures, less insight
has been obtained on alterations of molecular networks and
signaling pathways from the large amount of data generated in
such studies. By applying the statistical approach of Gene Set
Enrichment Analysis (GSEA) to gene expression data, interacting
genes whose expression levels are coordinately changed can be
explored [5]. The GSEA method takes into consideration the
expression of all genes within an annotated gene set/pathway.
There are several databases and gene set definitions linking genes
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24419by their functional annotations. The most widely used is the Gene
Ontology (GO) database, which is based on a combination of
computational and manual assignment of genes to GO terms [6].
However, these terms do not correspond directly to known
pathways. The Kyoto Encyclopedia of Genes and Genomes
(KEGG) is a molecular pathway database of manually curated and
frequently updated metabolic, regulatory, and signaling pathways
[7]. Using this conservatively annotated database, the redundancy
in the nested structure of gene associations represented by GO
terms can be avoided. Compared to individual gene expression
Figure 1. Important genes in colorectal cancer development. A) Key genes targeted in the various CRC phenotypes during development from
precursor lesions to carcinomas. Genes in bold represent MAPK, PI3K, and TP53 signaling networks, and their mutation status have previously been
determined [38]. B) The figure shows how part of the phosphatidyl inositol network interacts with the canonical PI3K pathway. Genes of which
mutation status data are used for association analyses in the current paper are colored in blue, pink and brown. Abbreviations: GPCR, G-protein
coupled receptor; RTK, receptor tyrosine kinase.
doi:10.1371/journal.pone.0024419.g001
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changes of genes within pathways, hence altered signaling
pathways and genes herein not known to be involved in
carcinogenesis could be identified.
The importance of the canonical Phosphatidylinositol 3-kinase
(PI3K) pathway in cancer has been established in numerous
publications during the last decade [8]. This signaling network has
impact on several cancer-critical phenotypes such as cell
proliferation, survival, metabolism, and tumor growth [8]. A
branch of the network overlaps with the Phosphatidylinositol
signaling network which is mediating signals through Phospholi-
pase C (PLC) proteins (Figure 1B). This network probably
crosstalks with the MAPK and TP53 pathways, important
pathways in CRC development. The PLC protein family
comprises thirteen isozymes divided into six distinct subtypes, b,
c, d, e, f, and g, based on structure and regulatory activation
mechanisms. The PLC isozymes contain several common
domains, as well as subtype specific domains, that can make them
capable of regulating lipase-independent reactions [9]. Further,
they are soluble and mainly localized in the cytosol, but become
translocated to the plasma membrane in response to receptor
activation [10]. At the membrane they hydrolyze phosphatidyli-
nositol (4,5)-phosphate (PIP2) and generate the important second
messenger diacylglycerol (DAG) and inositol 1,4,5-triphospate
(IP3). Imbalance of phosphoinositide levels (PIP2 and PIP3) has
been shown to induce defects in channel activity, trafficking, and
normal cell polarity [9]. Thus, correct regulation of the
phosphoinositides by e.g. PLC enzymes is essential and aberrant
regulation contributes to various human disorders, including
cancer [9].
By exploring gene expression of predefined biological processes
and molecular circuits in two CRC and normal colonic mucosa
datasets obtained using different microarray platforms, a list of
pathways significantly altered by differential gene expression in
CRCwasidentified.Weselectedthe‘‘Phosphatidylinositolsignaling
network’’ and two of the deregulated components therein, PLCD1
(HGNC:9060) and PLCE1 (HGNC:17175), for detailed studies and
compared the findings with clinicopathological data and mutation
status of several genes known to be altered in CRC.
Results
Deregulated KEGG pathways in CRCs
In total, 152 KEGG gene sets were present in both gene
expression datasets. From these, GSEA revealed 33 significantly
upregulated and 49 significantly downregulated biological pro-
cesses and pathways in CRC compared to normal colonic mucosa
(P#0.05; Figure 2). Eleven significantly altered networks had
opposite enrichment scores between the datasets, whereas 44 were
found significantly altered in only one of the datasets. KEGG
networks significantly deregulated in CRC compared to normal
mucosa in both datasets are listed in Table S1 (n=82). The fact
that these pathways were found significantly altered (P#0.05) in
two independently analyzed datasets, obtained from different
microarray platforms, gives a risk of only 1/400 for each pathway
to be included as significantly altered merely by chance. Hence, no
additional correction for multiple testing is performed (this also
accounts for the upper part of Table 1). The 82 networks include
gene sets responsible for general cancer cell traits, various
metabolic circuits as well as more renowned signaling cascades
such as the TP53 and MAPK pathways. Plots of gene expression
levels in CRC samples versus normal colonic mucosa specimens for
all genes in the three most upregulated and the three most
downregulated networks in CRC are shown in Figure S1, and
their statistically differentially expressed genes are listed in Table
S2.
The ‘‘Phosphatidylinositol signaling system’’
The ‘‘Phosphatidylinositol signaling system’’ was one of the
molecular pathways found to be downregulated in CRC
compared to normal mucosa, i.e. having more downregulated
than upregulated genes. A total of 22/59 and 27/76 genes passing
the quality criteria were significantly deregulated in CRC in the
AB and HuEx datasets, respectively (Figure 3, Table 1). Of the 11
Figure 2. Venn diagram displaying significantly deregulated signaling pathways in the AB and HuEx gene expression datasets. The
diagram shows that the results of the GSEA were highly reproducible with 33 and 49 pathways jointly up- and downregulated across the two
datasets, respectively.
doi:10.1371/journal.pone.0024419.g002
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diacylglycerol kinases, and phospholipases, two were significantly
upregulated, whereas nine were downregulated. Interestingly, we
found four downregulated lipases (PLCD1, PLCD3, PLCE1, and
PLCG2) that were closely related isozymes belonging to the
Phospholipase C (PLC) family of proteins. PLCD1 and PLCE1, the
Table 1. Significantly deregulated genes within the ‘‘Phosphatidylinositol signaling system’’.
Gene symbol P-Value AB Log fold change AB P-Value HuEx Log fold change HuEx
Genes significantly altered in two datasets
Upregulated genes
INPP5D 5.4E-05 2.2 1.4E-03 0.8
PIK3R3 2.9E-02 1.0 4.8E-03 0.9
Downregulated genes
DGKA 3.4E-02 21.2 9.7E-03 20.6
DGKD 6.0E-04 21.2 4.9E-06 20.6
IMPA2 1.7E-12 21.7 1.0E-05 21.0
ITPKA 6.9E-04 21.7 7.1E-03 20.4
PIP5K1B 1.1E-02 214.9 1.4E-03 21.1
PLCD1 1.9E-04 21.9 2.0E-09 20.9
PLCD3 2.1E-04 21.3 1.4E-07 20.8
PLCE1 6.2E-05 22.9 6.1E-05 21.7
PLCG2 1.7E-02 21.4 1.3E-02 20.4
Genes significantly altered in one dataset
Upregulated genes
CDIPT 3.0E-03 0.9 7.0E-02 0.3
CDS2 2.4E-02 0.7 4.5E-01 0.1
DGKZ 9.3E-03 0.9 6.2E-01 20.1
PIK3C2A 2.4E-01 20.4 9.4E-03 0.5
PIK3CA 9.7E-01 0.0 1.8E-02 0.5
PIP5K1A 1.0E-01 20.9 1.7E-02 0.4
PTPMT1 4.8E-03 0.7 - -
Downregulated genes
CALM1 - - 2.0E-04 20.4
CALM2 5.7E-02 20.4 1.7E-02 20.5
DGKB - - 7.4E-04 20.3
IMPA1 1.5E-02 20.8 5.9E-02 20.5
INPP5A 3.0E-01 20.6 1.2E-04 20.6
INPP5J - - 3.7E-04 20.5
INPP5K - - 3.2E-02 20.3
ITPK1 3.0E-01 20.3 6.7E-04 20.5
PI4KA - - 3.9E-02 20.3
PIB5PA 4.5E-04 21.2 - -
PIK3CG - - 2.3E-02 20.7
PIK3R5 2.7E-04 22.0 2.3E-01 20.1
PIK4CA 7.4E-04 20.8 - -
PIP5K1C 1.3E-01 0.6 1.5E-04 20.3
PIP5K3 2.5E-03 21.0 - -
PLCB2 8.0E-01 0.1 1.0E-02 20.3
PLCD4 - - 1.9E-04 20.4
PRKCA 1.4E-02 20.9 7.9E-01 20.1
PRKCB 5.9E-01 20.3 1.2E-02 20.5
SKIP 6.8E-03 20.7 - -
Genes in bold were found significantly deregulated across both gene expression datasets (upper part of the table). Due to multiple testing, P-values of genes
significantly altered in only one of the datasets should be interpreted with caution (lower part of the table; see Results).
doi:10.1371/journal.pone.0024419.t001
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most significantly downregulated compared with the normal
mucosa samples in the HuEx and AB datasets, respectively, were
chosen for further validation.
Validation of PLCD1 and PLCE1 mRNA expression
From quantitative reverse transcription-PCR, PLCD1 and
PLCE1 were clearly repressed in cancerous tissue samples
compared with normal mucosa (P=3 610
216 and P=4 610
215),
confirming the downregulation found in the microarray expression
data (Figure 4). All the nineteen analyzed colon cancer cell lines
also displayed significant repression of the two genes compared to
normal mucosa (P=2 610
210 and P=1 610
28).
PLC expression values associated to genetic and
clinicopathological variables
Interestingly, there were strong associations between low
expression of both PLCD1 and PLCE1 and KRAS mutations in
CRC samples (Table 2). Furthermore, reduced expression levels of
PLCD1 were significantly associated with TP53 mutations and the
MSS phenotype. For both PLC genes, the expression levels were
reduced in more advanced disease stages. Expression values of
PLCE1 were decreased in stage II (P=0.06) and significantly
decreased in stage III tumors (P=0.005), compared to stage I
tumors. However, this was not the case for distant metastatic disease
(stage IV). The same trend was also seen for PLCD1, where
expression levels were significantly decreased in stage III compared
to stage I (P=0.03). No associations were found between PLCD1
and PLCE1 expression and mutations in BRAF, PIK3CA,o rPTEN.
For Table 2 it should be noted that due to multiple testing (n=16),
there is a risk of false significant associations.
Promoter methylation analysis of PLCD1 and PLCE1
PLCD1 and PLCE1 could be targets for promoter methylation
since their expression levels were low in CRC compared with
normal colonic mucosa samples. Both genes possess CpG islands
in their promoters and their expression became upregulated in cell
lines treated with epigenetic reactivating agents (5-aza-29deoxycy-
tidine; AZA and Trichostatin A; TSA). Complete or partial
methylation of the PLCD1 promoter was found in 79% (15/19) of
the colon cancer cell lines, detected by qualitative as well as
quantitative methylation-specific polymerase chain reaction (MSP
and qMSP, respectively). The remaining four cell lines were
completely unmethylated. The methylation status of the colon
cancer cell lines was confirmed by bisulfite sequencing using two
non-overlapping sets of primer pairs covering altogether 69 CpG
sites. There was no association between methylation and MSI-
status of the cell lines. For primary carcinomas, only nine out of 70
(13%) samples were methylated, as assessed by MSP and qMSP.
The majority of the tumors considered positive for methylation
displayed low PMR values (median 5.69). Interestingly, eight of
the nine methylated tumors were MSI, yielding a methylation
frequency of 40% (8/20) in this subgroup. Furthermore, all the
methylated MSI tumors had mutations in BRAF, whereas the
methylated MSS tumor was wild type. For PLCE1, only one of 19
colon cancer cell lines showed promoter methylation. This was
confirmed by bisulfite sequencing covering 47 CpG sites. Due to
the low PLCE1 promoter methylation frequency among the cell
lines, tissue samples were not subjected to methylation analyses.
Discussion
By exploring gene expression within predefined molecular
pathways in two independent CRC transcriptome datasets, we
have identified several molecular networks and components
therein that are deregulated in CRC and might contribute to
carcinogenesis.
The ‘‘Cell cycle’’ was not surprisingly the most extensively altered
gene set in our analyses. Its proper regulation is essential for ensuring
correct transmission of genetic information from one generation to
the next, thus deregulation of several cell cycle components is defined
as cancer hallmarks. Our finding is in line with several comparable
studies of CRC where gene sets restricted exclusively to cancer-
relatedpathways[11]andmultipleonlinedatabasescomprisingmore
general pathways, have been explored [12–14]. CRCs displayed
expression changes in numerous metabolic pathways, i.e. ‘‘Oxidative
phosphorylation’’ wasthe mostsignificantlydownregulatedmetabolic
Figure 3. Venn diagram displaying significantly deregulated genes within the ‘‘Phosphatidylinositol signaling system’’. Altogether
38 genes in the ‘‘Phosphatidylinositol signaling system’’ were altered in one or both dataset, eleven genes were found deregulated across both
datasets.
doi:10.1371/journal.pone.0024419.g003
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pyrimidines, and N-glycans, in addition to the ‘‘Pentose phosphate
pathway’’ were upregulated. The purine and pyrimidine metabolism
were newly found to be upregulated also in adenomas compared to
normal mucosa, indicating that alterations of these networks are early
events in tumorigenesis [14]. Reprogramming of energy metabolism
was recently launched as an emerging hallmark of cancer, and the
findings are also in agreement with what Otto Warburg described
half a century ago, referred to as the ‘‘Warburg effect’’. He identified
a shift in glucose metabolism from oxidative phosphorylation to
aerobic glycolysisin tumor cells [15]. Limiting the metabolism largely
to glycolysis allows conversion of glycolytic intermediates into
nucleosides and amino acids. This in turn facilitates biosynthesis of
macromolecules and organelles required for the increased production
Figure 4. Boxplot showing markedly reduced expression levels of PLCD1 and PLCE1 in colorectal cancer. The expression levels of PLCD1
and PLCE1 in CRC and colon cancer cell lines assessed by RT-PCR were significantly downregulated compared to normal colonic mucosa.
doi:10.1371/journal.pone.0024419.g004
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various forms of DNA repair mechanisms were also found
deregulated in our datasets. These fundamental systems are
frequently put out of play not only in cancer, but also in other
diseases and syndromes, underscoring the severity of not being able to
copy the DNA or repair mistakes in a correct manner.
In addition to more general cancer cell traits, central circuits in
CRC like MAPK-, TP53-, and Phosphatidylinositol signaling
systems, where usually one or a few prominent players are
reported to be frequently altered at the DNA level (due to point
mutations, amplifications, and/or deletions; [8,16]), were found
significantly deregulated in our analyses. This implies that altered
gene expression of several less ‘‘famous’’ members in the pathways
also contribute in colorectal carcinogenesis. In this study we
observed that genes like PIK3CA and PTEN were expressed in
tumor samples, but not at significantly different levels from normal
colon tissue in both datasets. We and others have shown that these
genes often suffer from alterations on DNA- or protein levels
rather than by changes in mRNA expression [8,17–19].
In order to reveal additional genes in the ‘‘Phosphatidylinositol
signaling system’’ involved in tumorigenesis, we explored the
expression level of all its components as annotated in KEGG. Both
inositol phosphatases, diacylglycerol kinases, and phospholipases
were found to have altered expression. Among the phospholipase
enzymes, members of the Phospholipase C family were well
represented, indicating an important role for this family in CRC.
This was underscored by RT-PCR analyses validating that the
expression levels of PLCD1 and PLCE1 were extensively
downregulated in CRC compared to normal colonic mucosa.
The repression of PLCD1 is in accordance with the results
presented by Nomoto and colleagues in 1995, where they report
undetectable levels of PLCD1 protein in eight colon cancer cell
lines and decreased levels in twelve of thirteen colon carcinomas
compared with their paired normal mucosa sample [20]. Several
groups have suggested a role for PLCD1 in regulating the cell
cycle G1/S-checkpoint, however, there are contradicting results to
whether it has an oncogenic or tumor suppressive function [21–
23]. Based on the present findings, we suggest the latter function of
PLCD1 in CRC. Similar results have also been reported for
esophageal squamous cell carcinomas (ESCC), gastric and breast
cancer [21,24–26]. Interestingly, the low expression levels of
PLCD1 were strongly associated with mutations in TP53 and
KRAS as well as to tumors of the MSS phenotype; although the
biological significance of these associations remains to be
determined.
The observed repression of PLCE1, the second gene investi-
gated in detail, is supported by the results from Sorli et al.w h o
also demonstrated significantly reduced mRNA expression levels
in colon and rectum cancer samples and colon cancer cell lines,
as well as by Wang and colleagues who reported a frequency of
36% loss of heterozygosity (LOH) of 10q23 where PLCE1 is
located and downregulation of PLCE1 in 21/50 colorectal cancer
samples compared with matched normal tissue [27–29]. Further-
more, we observed that the expression levels of PLCE1 were
decreasing with more advanced stages, indicating that the
repression of this gene is beneficial for cancer progression.
Notably, the level appears to rise when reaching metastatic
disease (stage IV), a phenomenon previously described for PLCD1
and PLCD3 in breast cancer [24]. Nevertheless, caution should be
made when interpreting the results for the present stage IV
group, as only seven tumors are included. The expression levels
of PLCD1 and PLCE1 were correlated, and as expected, reduced
expression of both genes was associated to more advanced tumor
stages (data not shown). However, the individual expression levels
and the expression levels of both genes combined were not
correlated with patient survival (data not shown). Intriguingly, as
for PLCD1, low expression of PLCE1 was strongly associated with
mutations in KRAS. Since PLCE1 is found to be both an
upstream and downstream effector of Ras family proteins [30],
the correlation of mutated KRAS with the reduced expression
levels most likely plays a critical role in CRC tumorigenesis.
Further, it was recently reported that overexpression of PLCE1 in
a colon cancer cell line inhibited tumor cell proliferation, reduced
number of colonies formed, reduced migration, and increased
apoptosis [29], suggesting a tumor suppressive role for this gene
in CRC.
We then investigated whether the reduced expression levels of
PLCD1 and PLCE1 could be due to promoter hypermethylation.
This is a common way to inactivate tumor suppressor genes, and
both phopholipases have been put forward as candidates for
promoter hypermethylation [27]. However, this has so far only
been confirmed in PLCD1 within a range of 52–62% methylation
in ESCC, gastric and breast cancer [21,25,26]. Our results from
qMSP and bisulfite sequencing cannot confirm PLCE1 as a target
for this type of epigenetic silencing, and despite high frequency of
methylation in colon cancer cell lines, methylation in the PLCD1
promoter can only explain reduced expression in a subgroup of the
carcinomas. Interestingly though, we discovered that all but one of
the methylated tumors were MSI, yielding a methylation
frequency of nearly forty percent among carcinomas with defect
mismatch repair. Additionally, the methylated MSI tumors were
localized in the right side of the bowel and had BRAF mutation, in
line with the CIMP phenotype [3].
By subjecting two CRC transcriptome datasets to GSEA, we
have identified a number of statistically significant deregulated
gene sets in CRC, and shown that this approach can guide
discovery of novel molecular targets and biomarkers for cancer.
Verification analyses of selected genes within one of the identified
deregulated signaling pathways, PLCD1 and PLCE1, confirmed
reduced levels of these transcripts in CRC compared to normal
mucosa samples. Both a tumor suppressive and tumor promoting
role of these genes and protein products have been suggested in
relation to cancer development, depending on tissue of origin [9].
The present data support a tumor suppressive role of PLCD1 and
PLCE1 in CRC, which for PLCD1 possibly can be explained by an
epigenetic mechanism in microsatellite unstable carcinomas.
Table 2. P-values for associations of PLCD1 and PLCE1 mRNA
expression values with clinicopathological and mutation data.
PLCD1 PLCE1
MSI/MSS 0.01 0.47
KRAS mut 0.005 0.006
BRAF mut 0.23 0.83
PTEN mut 0.91 0.74
TP53 mut 0.002 0.16
PIK3CA mut 0.48 0.98
Tumor stage 0.10 0.05
Localization 0.45 0.20
The expression values of PLCD1 and PLCE1 in CRC samples (n=70) were
compared to MSI status, mutations in various genes, tumor stage (I–IV) and
localization of the tumor (right, left, rectum).
doi:10.1371/journal.pone.0024419.t002
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Ethics statement
Written informed consent was obtained from all subjects
included. All samples were retrieved from research biobanks as a
part of research projects approved according to national ethical
guidelines. The biobank series have been registered according to
national legislation and is approved by the Regional Committee
for Medical Research Ethics (REK South-East S-09282c2009/
4958, Biobank 2781; REK South: 2003, S-02126, Biobank 296-
2005-174211).
Transcriptome datasets
Two independent colorectal tissue transcriptome profiling
datasets previously generated in our laboratory were used for this
GSEA study [31,32]. The raw data are accessible through the
NCBI’s Gene Expression Omnibus public repository for micro-
array data (accession numbers GSE25071 and GSE24550). The
first dataset includes gene expression profiles from 46 CRCs and
four normal colonic mucosa specimens obtained using the Applied
Biosystems 1700 platform (Applied Biosystems by Life Technol-
ogies, Foster City, CA, USA; AB) [31]. The second gene
expression dataset contains 91 CRCs and six normal colonic
mucosa specimens generated using the Affymetrix GeneChip
Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA;
HuEx) [32]. There were no overlapping samples between the two
microarray datasets. A summary of the clinical data for patients
included in the datasets can be found in Table S3.
Tissue samples and cancer cell lines
The patient samples included in target verification analyses
constituted a subset of the tumors used in the HuEx dataset
(n=70), and 17 normal colonic mucosa samples (including six
from the HuEx dataset). All samples were taken from patients
undergoing primary surgery for CRC at Oslo University Hospital,
Aker, Oslo, between 2005 and 2008. The normal colonic mucosa
samples were taken from disease-free areas in the resection margin
of the CRC specimens ($10 cm from the tumor). A clinicopath-
ological description can be found in Table S4.
Nineteen colon cancer cell lines (Co115, Colo320, EB, FRI,
HCT15, HCT116, HT29, IS1, IS2, IS3, LoVo, LS1034, LS174T,
RKO, SW48, SW480, TC7, TC71, and V9P) were included in
the study, and are thoroughly described in [33]. These were
cultured under standard conditions which will be given upon
request. Six of the cell lines (HCT15, RKO, SW48, HT29,
LS1034, and SW480) were subjected to epigenetic treatment using
the demethylating drug AZA (Sigma-Aldrich, St. Louis, MO,
USA; 1 mM for 72 hours), the histone deacetylase inhibitor TSA
(Sigma-Aldrich; 0.5 mM for 12 hours), and a combination of both
drugs (1 mM AZA for 72 hours and 0.5 mM TSA added the last
12 hours). In parallel, the same cell lines were cultured without
treatment for 72 hours. All commercially available cell lines were
authenticated using AmpFLSTR Identifiler PCR Amplification
Kit (Applied Biosystems).
Isolation of nucleic acids
DNA from fresh-frozen colonic tissue and colon cancer cell lines was
extracted by a standard phenol/chloroform protocol. RNA from
tumor tissue was extracted using the Qiagen AllPrep DNA/RNA Mini
Kit (Qiagen GmbH, Hilden, Germany), whereas RNA from normal
colonic mucosa samples and colon cancer cell lines was isolated by the
Ambion RiboPure
TM Kit (Life Technologies, Carlsbad, CA, USA)
and Trizol (Invitrogen, Carlsbad,C A ,U S A ) ,r e s p e c t i v e l y .A l l
procedures were performed according to the manufacturers’ protocols.
Gene Set Enrichment Analysis (GSEA)
For GSEA gene sets were defined according to the KEGG
pathway collection (Homo sapiens (human) Release 53.0) [7]. The
analysis was conducted using GSEABase package in Bioconduc-
tor/R version 2.9.2 [34]. The two microarray gene expression
datasets of CRC versus normal colonic mucosa were independently
subjected to GSEA. Data preprocessing was performed as
previously described [31,32]. Interquartile range (IQR) was used
as a measure of variability. Genes with IQR ,0.5 were excluded
from further analyses with GSEA. For genes targeted by multiple
transcript clusters (HuEx) or probes (AB), the reporter with largest
variability was used. Genes not assigned to any KEGG pathways
were also excluded from the analysis. A total of 3,361 and 4,797
genes with an annotated role in 205 and 220 KEGG pathways
were evaluated for the AB and HuEx datasets, respectively.
Pathways that included less than 10 annotated genes were
removed from further analysis, leaving 167 and 185 pathways in
the respective datasets. Two-sided, two-class t-tests assuming equal
variances across CRC and normal samples were performed for all
included genes. A gene set enrichment score was calculated as the
sum of observed t-statistics for the genes in the set, divided by the
square root of the number of genes in the set. Gene set P-values
were computed based on the vector of probabilities of the t-
statistics across the included genes [35].
Validation of PLCD1 and PLCE1 expression levels by
quantitative Reverse Transcription-PCR
Total RNA from CRC tissue and normal mucosa samples was
converted to cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). The cDNA of two
endogenous controls, ACTB (Hs99999903_m1) and GUSB
(Hs99999908_m1), as well as cDNA of the genes PLCD1
(Hs00979908_m1) and PLCE1 (Hs00275279_m1) was amplified
separately in 384 well-plates as described by the manufacturer
(Applied Biosystems). Gene expression was measured real-time
using the 7900 HT Sequence Detection System (Applied
Biosystems). The samples were analyzed in triplicates and the
median value was used for data analysis. A serial dilution of cDNA
from the Universal Human Reference RNA (Agilent, Santa Clara,
CA, USA) was used to generate the standard curve. The
expression levels of PLCD1 and PLCE1 were normalized against
the mean value of the endogenous controls.
Bisulfite treatment and promoter methylation assay
design
Prior to qualitative and quantitative MSP and bisulfite
sequencing, 1.3 mg DNA from each sample was sodium bisulfite
treated using the Epitect Bisulfite Kit (Qiagen) according to the
manufacturer’s protocol. The DNA cleansing was performed using
a QiaCube (Qiagen), and the final elution volume was set to 40 ml.
Primers for MSP and bisulfite sequencing were designed using
the Methyl Primer Express v.1 software (Applied Biosystems),
whereas primers and probe for the qMSPs were designed using the
Primer Express v3.0 software (Applied Biosystems). Primers were
purchased from Medprobe (Oslo, Norway) and the probe from
Applied Biosystems. Primer and probe sequences, product
fragment lengths and conditions are listed in Table S5. See Figure
S2 for primer and probe locations.
Qualitative methylation-specific polymerase chain
reaction
The promoter methylation status of both PLCD1 (NM_006225.3)
and PLCE1 (NM_016341) was analyzed by MSP using the
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verified by a second round of PCR. Bisulfite modified SssI
methyltransferase (New England Biolabs, Ipswich, MA,
USA) treated human placental DNA (Sigma-Aldrich, St.Louis,
MO, USA) and DNA from normal lymphocytes served as
positive controls for the methylated and unmethylated reaction,
respectively. Water was used as negative control in both
reactions.
Quantitative methylation-specific polymerase chain
reaction
The PLCD1 promoter was also analyzed by quantitative MSP
according to a protocol previously described [36]. ALUC4
was used as an internal reference to normalize for the amount
of input DNA. The level of DNA methylation was calculated
as Percent of Methylated Reference (PMR) by the follow-
ing equation: [(PLCD1/ALU)
sample /( PLCD1/ALU)
positive control]
6100. Samples with a PMR value exceeding the highest values
of normal mucosa samples, i.e. PMR.0, were considered
methylated.
Bisulfite sequencing
Bisulfite sequencing of the PLCD1 and PLCE1 gene promoters
were performed in nineteen colon cancer cell lines. Seventy CpG
sites in the PLCD1 promoter were analyzed, including the MSP
and qMSP primer and probe binding sites (see Figure S2). For the
PLCE1 promoter 47 CpG sites were analyzed, including the MSP
primer binding sites. The bisulfite sequencing was carried out as
described in Lind et al. [37].
Molecular phenotypes and gene mutation status
Microsatellite instability/stability and mutation status of all
exons of TP53 (HGNC:11998) and PTEN (HGNC:9588), as
well as of mutation hot spots in KRAS (HGNC:6407; codon 12, 13,
and 61), BRAF (HGNC:1097; codon 600), and PIK3CA
(HGNC:8975; exon 9 and 20) have previously been determined
(Table S4) [38].
Statistics on clinicopathological data
Statistical analyses related to clinicopathological and mutational
data were conducted using PASW Statistics v.18.0 (SPSS Inc., IL,
USA). Associations between gene expression levels and clinico-
pathological features were analyzed by Mann-Whitney-Wilcoxon
(MWW) test or Kruskal-Wallis test. The MWW test was also used
to examine expression level differences between normal colonic
mucosa, CRC samples, and colon cancer cell lines. All reported P-
values are two-sided, and values #0.05 were considered
statistically significant.
Supporting Information
Figure S1 Plots showing gene expression of the most
significantly up- and downregulated pathways. Gene
expression in CRC versus normal colonic mucosa for the three
most significantly up- and downregulated pathways in two gene
expression datasets, A–C and D–F, respectively. The plots are
based on values from the HuEx dataset, but are representative also
for the AB dataset.
(TIF)
Figure S2 Primers and probe location relative to
transcription start site. Promoter region of A) PLCD1
(NM_006225.3) and B) PLCE1 (NM_016341) with location of all
primers and the probe used in the present study. Vertical bars
represent CpG sites, whereas +1 designate transcription start site.
Abbreviations: Bisulf.seq, bisulfite sequencing; MSP, qualitative
methylation-specific polymerase chain reaction; qMSP, quantita-
tive methylation-specific polymerase chain reaction; ps, present
study; s, sense; as, antisense.
aPrimers from Hu et.al, Oncogene, 28,
2009.
(TIF)
Table S1 Significantly deregulated KEGG pathways in
CRC compared to normal colonic mucosa across two
gene expression datasets.
*the total number of genes in-
cluded in each pathway after quality controls
1 values less than
2.6E-162.
(DOC)
Table S2 Genes significantly deregulated in the most
significantly up- and downregulated pathways in CRC.
The three most significantly upregulated pathways with the
significantly differentially expressed genes in each/both datasets
are presented in the upper part of the table. Similarly, the lower
part of the table lists the three most significantly downregulated
pathways and the differentially expressed genes. Of notice, KEGG
pathway 00980: Metabolism of xenobiotics by cytochrome P450
were more downregulated than KEGG pathways 00830 and
00280 displayed in the table, but were due to substantial overlap
with KEGG pathway 00982: Drug metabolism – cytochrome
P450 replaced with the next pathways on the list.
(DOC)
Table S3 Summary of patient clinical data in the
transcriptome datasets.
aTumor stage according to Union
for International Cancer Control (UICC)/American Joint Com-
mittee on Cancer (AJCC) staging system.
(DOC)
Table S4 Clinical, pathological, and molecular data for
patient samples included in the validation and methyl-
ation analyses.
aTumor stage according to UICC/AJCC
staging system Abbreviations: M, male; F, female; MMR,
mismatch repair; MSI, microsatellite instable; MSS, microsatellite
stable; Wt, wild type; Mut, mutated; Unmeth, unmethylated;
Meth, methylated.
(DOC)
Table S5 Primers and probe used for qualitative and
quantitative methylation-specific polymerase chain re-
action and bisulfite sequencing. For PLCD1 (NM_006225.3)
the MSP primers were obtained from Hu et al. (Oncogene, 28,
2009, p.2466-75) whereas the bisulfite sequencing was per-
formed with primers from Hu et al. combined with primers
specifically designed for the present study. For PLCE1
(NM_016341), all primers were designed for the present study.
Abbreviations: MSP, methylation-specific polymerase chain
reaction; M, methylated-specific primers; U, unmethylated-
specific primers; qMSP, quantitative methylation-specific poly-
merase chain reaction; MGB, minor groove binder; BS, bisulfite
sequencing.
(DOC)
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